
-
Heavy rains leave 30 dead in Chinese capital
-
Gunman dead in New York after Midtown shooting: police
-
Colombian ex-president Uribe found guilty of witness tampering
-
Osaka to work with Wiktorowski on trial after Mouratoglou split
-
Alvaro Uribe: Colombia's first ex-president convicted of a crime
-
Aussie qualifier schools young gun Fonseca in Toronto
-
Second Guardians pitcher on leave under MLB gambling probe
-
China and US wrap first day of trade talks
-
EU car industry sees relief - and pain - in US trade deal
-
Hundreds of Sudanese refugees in Cairo take up chance to return home for free
-
Tinubu receives Nigerian women's team after Africa Cup victory
-
AI Ray-Ban Meta glasses help EssilorLuxottica boost sales
-
Europe's carmakers still nervous despite EU-US trade deal
-
Veteran Vos takes Tour de France yellow after Wiebes stage win
-
EU defends Trump trade deal in face of backlash
-
England's Lionesses return to heroes' welcome after Euro 2025 glory
-
Hunger must never be 'weapon of war', UN chief tells Africa food summit
-
Heineken shares plummet as beer sales dry up
-
Trump slashes Russia ultimatum to '10 or 12 days'
-
Landslide kills four as rains lash northern China
-
Telegram's Durov questioned in France over alleged illegal content on app
-
Home from home: Trump showcases his resorts in golf diplomacy
-
EU accuses online giant Temu over sale of 'illegal' products
-
'No alternative' to two-state solution for Israel, Palestinians
-
US plan to destroy contraceptives sparks uproar
-
Turkey battles wildfires as heatwave grips Med
-
Dollar rises on EU-US trade deal but European stocks turn sour
-
Thai-Cambodia evacuees hail truce news with mixed emotions
-
Rivals laud 'phenomenally talented' 12-year-old swim sensation
-
Major Israeli rights groups brand Gaza campaign 'genocide'
-
EU defends Trump trade deal facing backlash
-
McIntosh wins again at swimming worlds as Yu, 12, just misses out
-
Trump says Gaza ceasefire 'possible' amid Starmer talks
-
McIntosh wins second Singapore gold, China prodigy Yu fourth
-
Hunger must never be 'weapon of war': UN chief
-
Brussels says EU-US deal 'better than trade war' with Trump
-
Three things we learned from Belgian F1 Grand Prix
-
Walsh defies illness in US camp to win butterfly world gold
-
Qin beats Olympic champ Martinenghi for 100m breaststroke world gold
-
Ireland's 'economic miracle' at risk from tariffs
-
Stock markets, dollar rise on EU-US trade deal
-
England's Lionesses head home to party after Euro glory
-
Philippine flooding centre stage at Marcos state of nation speech
-
Thailand and Cambodia agree truce after five days of fighting
-
Israeli settlers attack West Bank Christian village
-
Food arrives in Gaza after Israel pauses some fighting
-
Starmer to press Trump on Gaza, trade in Scotland talks
-
Jamie Overton added to England squad for fifth Test against India
-
China to offer childcare subsidies in bid to boost birth rate
-
Artists, scientists breathe life into prehistoric woman
RIO | -1.46% | 62.19 | $ | |
CMSC | 0.07% | 22.5 | $ | |
SCU | 0% | 12.72 | $ | |
RBGPF | 0% | 75 | $ | |
CMSD | 0.04% | 22.9 | $ | |
SCS | 2.49% | 10.85 | $ | |
BTI | -0.91% | 51.78 | $ | |
BCC | -1.61% | 86.74 | $ | |
BCE | -1.55% | 23.83 | $ | |
NGG | -2.6% | 70.32 | $ | |
RELX | -1.85% | 51.77 | $ | |
RYCEF | -0.08% | 13.14 | $ | |
GSK | -1.39% | 37.45 | $ | |
JRI | -0.46% | 13.03 | $ | |
BP | 1.44% | 32.67 | $ | |
VOD | -2.42% | 11.16 | $ | |
AZN | -1.16% | 71.83 | $ |

First post-Covid jab claims land in German courts
German courts will from Monday begin examining a series of claims over adverse effects suffered after coronavirus vaccinations, more than two years after one of the world's fastest and most extensive innoculation campaigns.
In the face of a deadly pandemic that emerged in early 2020, which prompted border closures and lockdowns that trapped millions of people in their homes, the arrival of Covid vaccines had been widely hailed as a life-saver.
But the jabs, which had been developed at breakneck speed and granted early approval for usage, are now the focus of legal claims in several countries including France and Britain as the plaintiffs say the vaccines damaged their health.
In Germany, a court in Hamburg will be the first to hear a case brought against homegrown vaccine manufacturer BioNTech, which, together with US giant Pfizer, produced the first mRNA vaccine Comirnaty.
The claimant reported suffering effects including "pain in the upper body, swelling of the extremities, exhaustion, fatigue and sleeping disorders" after taking the jab, the court said.
She is seeking 150,000 euros ($162,000) in damages and recognition that the "defendant is bound to provide material damages", the court added.
Her lawyer Thomas Ulbrich, who is also representing another 250 people in similar cases, said his clients were "all healthy" before suffering from symptoms, allegedly following their jabs.
He believes that the medical files he has on hand offer a link between the vaccines and the symptoms experienced by his clients.
- 'Rocky and long road' -
BioNTech's mRNA vaccine, a scientific breakthrough, had been granted conditional marketing authorisation as early as December 21, 2020, by the EU regulatory authority EMA.
Similar authorisation for Moderna, another mRNA vaccine maker, swiftly followed.
With fears of catching the disease running high, the vaccines were pre-ordered by governments even during their development phases, and deployment swiftly followed once regulatory authorities gave their approval.
But the new generation of inoculations also sparked a wave of vaccine sceptics questioning the safety of the jabs.
Out of 192 million jabs given in Germany, the country's medecines regulator, the Paul Ehrlich Institute, said 338,857 suspected cases of side effects were reported, including 54,879 severe reactions.
Among the worst cases, "the symptoms are very different, they vary from stroke to thrombosis to cardiac diseases", said another German lawyer, Joachim Caesar-Preller, who represents 140 clients making similar claims.
He is seeking up to one million euros in damages per case -- plus interest -- but concedes that a "rocky and long road" lies ahead in the legal battles.
- 'Not an isolated case' -
A key point for the courts is whether the side effects of the medication, when used correctly, surpass "a justifiable level according to the findings of medical science".
In other words, the effects have to be sufficiently serious to be taken into account, said Anatol Dutta, a professor at Munich University.
A claimant identified only as Kathrin K., 45, believes her symptoms are severe enough.
She said she lost a lot of weight after taking the vaccine and had to undergo several intestinal operations.
"I hate it when people tell me that I'm an isolated case," she said. "I'm not."
To address the question of causality, the courts would likely have to obtain expert advice.
Besides the legal avenue, claimants can also turn to the state for compensation for the loss of income.
More than 8,000 such applications had been made as of April, and so far about five percent have been successful, according to German media.
In a statement to AFP, BioNTech said that the number of liability claims made to the company is very small when compared to the number of doses it has delivered worldwide, and that each claim had to be examined individually.
"Justified liability claims would of course be met by BioNTech," it said, adding however that "no causal relationship between (the) health impairments presented and vaccination with Comirnaty has been proven" in the cases it had reviewed so far.
Another lawyer, Anja Dornhoff, advises her clients to establish a chronology and to get medical practitioners to document the development of their symptoms.
"I hope that people with post-vaccination syndromes can be taken seriously," she said.
R.Adler--BTB